Emerging pathways and promising agents with possible disease modifying effect in osteoarthritis treatment

Current Drug Targets

Volumn 15, Issue 6, 2014, Pages 635-661

  Jotanovic, Zdravko ^a   Mihelic, Radovan ^a   Sestan, Branko ^a   Dembic, Zlatko ^b  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Antibodies; Diphosphonates; Genetic therapy; Interleukins; Osteoarthritis; Selective estrogen receptor modulators; Stem cells

Indexed keywords

6 N (3 IODOBENZYL) ADENOSINE 5' N METHYLCARBOXAMIDE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADAMTS1 PROTEIN; BALICATIB; CALCITONIN; CANAKINUMAB; CINDUNISTAT; CLODRONIC ACID; COLECALCIFEROL; DIACEREIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ESTROGEN; GEVOKIZUMAB; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE INHIBITOR; OSTEOGENIC PROTEIN 1; PH 797804; PROTEINASE INHIBITOR; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID; ANTIRHEUMATIC AGENT;

CARTILAGE; HOMEOSTASIS AND REGULATION; HUMAN; INFLAMMATION; JOINT INSTABILITY; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SUBCHONDRAL BONE PLATE; SYNOVIUM; ANIMAL; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENE THERAPY; METABOLISM; PROCEDURES;

ANIMALS; ANTIRHEUMATIC AGENTS; CARTILAGE; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HUMANS; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 84899788872     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140306153115     Document Type: Review

References (253)

1. Judith Farley, Valeria C. Dejica and John S. Mort. Proteases and Cartilage Degradation in Osteoarthritis, Principles of Osteoarthritis-Its Definition, Character, Derivation and Modality-Related Recognition, Dr. Bruce M. Rothschild (Ed.), InTech, 2012. Available at: www.intechopen.com/books/principles-of-osteoarthritis-itsdefinition-character-derivation-and-modalityrelatedrecognition/ proteases-and-cartilage-degradation-in-osteoarthritis [Last accessed October 15, 2013]
2. Martel-Pelletier J, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone 2012; 51(2): 297-311.
3. Devy L, Dransfield DT. New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochem Res Int 2011; 2011: 191670.
4. Alcaraz MJ, Megías J, García-Arnandis I, et al. New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol 2010; 80(1): 13-21.
5. Roach HI. Potential directions for drug development for osteoarthritis. Expert Opin Drug Discov 2008; 3(5): 475-86.
6. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276(16): 12501-4.
7. Zhao H, Bernardo MM, Osenkowski P, et al. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem 2004; 279(10): 8592-601.
8. Sahebjam S, Khokha R, Mort JS. Increased collagen and aggrecan degradation with age in the joints of Timp3(-/-) mice. Arthritis Rheum 2007; 56(3): 905-9.
9. Nakashima K, Nakatsuka K, Yamashita K, et al. An in vitro model of cartilage degradation by chondrocytes in a three-dimensional culture system. Int J Biomed Sci 2012; 8(4): 249-57.
10. Leff RL, Elias I, Ionescu M, et al. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 2003; 30(3): 544-9.
11. Krzeski P, Buckland-Wright C, Bálint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007; 9(5): R109.
12. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebocontrolled, double-blind trial. Arthritis Rheum 2005; 52(7): 2015-25.
13. Tardif G, Reboul P, Pelletier JP, Martel-Pelletier J. Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Mod Rheumatol 2004; 14(3): 197-204.
14. Pratta MA, Yao W, Decicco C, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J Biol Chem 2003; 278(46): 45539-45.
15. Chockalingam PS, Sun W, Rivera-Bermudez MA, et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage 2011; 19(3): 315-23.
16. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276(16): 12501-4.
17. Troeberg L, Fushimi K, Khokha R, et al. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J 2008; 22(10): 3515-24.
18. Echtermeyer F, Bertrand J, Dreier R, et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009; 15(9): 1072-6.
19. Le Graverand-Gastineau MP. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets 2010; 11(5): 528-35.
20. Abramson SB, Amin AR, Clancy RM, Attur M. The role of nitric oxide in tissue destruction. Best Pract Res Clin Rheumatol 2001; 15(5): 831-45.
21. Pelletier JP, Jovanovic D, Fernandes JC, et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998; 41(7): 1275-86.
22. Pelletier JP, Lascau-Coman V, Jovanovic D, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999; 26(9): 2002-14.
23. Pelletier JP, Jovanovic DV, Lascau-Coman V, et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000; 43(6): 1290-9.
24. Hellio le Graverand MP, Clemmer RS, Redifer P, et al. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013; 72(2): 187-95.
25. Davies PS, Graham SM, MacFarlane RJ, et al. Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation. Expert Opin Investig Drugs 2013; 22(4): 423-41.
26. Fortier LA, Barker JU, Strauss EJ, et al. The role of growth factors in cartilage repair. Clin Orthop Relat Res 2011; 469(10): 2706-15.
27. Hunter DJ. Pharmacologic therapy for osteoarthritis--the era of disease modification. Nat Rev Rheumatol 2011; 7(1): 13-22.
28. Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013; 9(7): 400-10.
29. Hunter DJ, Pike MC, Jonas BL, et al. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010; 11: 232.
30. Mc Pherson R, Flechenshar K, Hellot S, Eckstein F. A randomized, double-blind, placebo controlled, multicenter study of rhFGF18 administered intraarticularly using single or multiple ascending doses in patients with primary knee osteoarthritis (OA), not expected to require knee surgery within 1 year. Osteoarthritis Cartilage 2011; 19 (Suppl. 1): S35-S36.
31. Attur M, Samuels J, Krasnokutsky S, Abramson SB. Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence? Best Pract Res Clin Rheumatol 2010; 24(1): 71-9.
32. Goldring MB. Anticytokine therapy for osteoarthritis. Expert Opin Biol Ther 2001; 1(5): 817-29.
33. Jotanovic Z, Mihelic R, Sestan B, Dembic Z. Role of interleukin-1 inhibitors in osteoarthritis: an evidence-based review. Drugs Aging 2012; 29(5): 343-58.
34. Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis 2012; 15(1): 69-77.
35. Shin K, Kim JW, Moon KW, et al. The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther 2013; 35(4): 431-9.
36. Baltzer AW, Ostapczuk MS, Stosch D, Seidel F, Granrath M. A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum. Orthop Rev (Pavia) 2013; 5(2): 59-64.
37. Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, doubleblind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011; 13(4): R125.
38. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39(1-2): 237-46.
39. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7(1): 33-42.
40. Pearle AD, Scanzello CR, George S, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 2007; 15(5): 516-23.
41. Livshits G, Zhai G, Hart DJ, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford Study. Arthritis Rheum 2009; 60(7): 2037-45.
42. Pelletier JP, Raynauld JP, Caron J, et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 2010; 69(12): 2095-101.
43. Pelletier JP, Fernandes JC, Brunet J, et al. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum 2003; 48(6): 1582-93.
44. Bogoyevitch MA, Boehm I, Oakley A, et al. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 2004; 1697(1-2): 89-101.
45. Badger AM, Bradbeer JN, Votta B, et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996; 279(3): 1453-61.
46. Ridley SH, Sarsfield SJ, Lee JC, et al. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol 1997; 158(7): 3165-73.
47. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42(12): 2532-42.
48. Amos N, Lauder S, Evans A, et al. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology (Oxford) 2006; 45(10): 1201-9.
49. Lauder SN, Carty SM, Carpenter CE, et al. Interleukin-1beta induced activation of nuclear factor-kappab can be inhibited by novel pharmacological agents in osteoarthritis. Rheumatology (Oxford) 2007; 46(5): 752-8.
50. Bar-Yehuda S, Rath-Wolfson L, Del Valle L, et al. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis Rheum 2009; 60(10): 3061-71.
51. Castañeda S, Roman-Blas JA, Largo R, Herrero-Beaumont G. Subchondral bone as a key target for osteoarthritis treatment. Biochem Pharmacol 2012; 83(3): 315-23.
52. Goldring SR. Role of bone in osteoarthritis pathogenesis. Med Clin North Am 2009; 93(1): 25-35, xv.
53. Hayami T, Pickarski M, Zhuo Y, et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006; 38(2): 234-43.
54. Pelletier JP, Troncy E, Bertaim T, et al. Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging. J Rheumatol 2011; 38(1): 118-28.
55. Brandt KD, Myers SL, Burr D, Albrecht M. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fiftyfour months after transection of the anterior cruciate ligament. Arthritis Rheum 1991; 34(12): 1560-70.
56. Spector TD. Bisphosphonates: potential therapeutic agents for disease modification in osteoarthritis. Aging Clin Exp Res 2003; 15(5): 413-8.
57. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007; 74(1): 32-8.
58. Saag KG. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not? Ann Rheum Dis 2008; 67(10): 1358-9.
59. Ham KD, Loeser RF, Lindgren BR, Carlson CS. Effects of longterm estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 2002; 46(7): 1956-64.
60. Ho TY, Santora K, Chen JC, et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. Bone 2011; 48(6): 1346-53.
61. Turner AS, Athanasiou KA, Zhu CF, et al. Biochemical effects of estrogen on articular cartilage in ovariectomized sheep. Osteoarthritis Cartilage 1997; 5(1): 63-9.
62. Sniekers YH, Weinans H, Bierma-Zeinstra SM, et al. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment-a systematic approach. Osteoarthritis Cartilage 2008; 16(5): 533-41.
63. Yan MZ, Xu Y, Gong YX, et al. Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism. Endocrine 2010; 37(1): 55-61.
64. Canpolat S, Tug N, Seyran AD, et al. Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats. J Physiol Biochem 2010; 66(1): 23-8.
65. Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004; 50(4): 1193-206.
66. Doschak MR, Wohl GR, Hanley DA, et al. Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. J Orthop Res 2004; 22(5): 942-8.
67. Karsdal MA, Byrjalsen I, Leeming DJ, Christiansen C. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord 2008; 9: 153.
68. Kadri A, Funck-Brentano T, Lin H, et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann Rheum Dis 2010; 69(8): 1533-8.
69. Moreau M, Rialland P, Pelletier JP, et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 2011; 13(3): R98.
70. Karsdal MA, Bay-Jensen AC, Henriksen K, Christiansen C. The pathogenesis of osteoarthritis involves bone, cartilage and synovial inflammation: may estrogen be a magic bullet? Menopause Int 2012; 18(4): 139-46.
71. Roman-Blas JA, Castañeda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther 2009; 11(5): 241.
72. Maneix L, Beauchef G, Servent A, et al. 17Beta-oestradiol upregulates the expression of a functional UDP-glucose dehydrogenase in articular chondrocytes: comparison with effects of cytokines and growth factors. Rheumatology (Oxford) 2008; 47(3): 281-8.
73. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006; 54(8): 2441-51.
74. Morisset S, Patry C, Lora M, de Brum-Fernandes AJ. Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol. J Rheumatol 1998; 25(6): 1146-53.
75. Claassen H, Schünke M, Kurz B. Estradiol protects cultured articular chondrocytes from oxygen-radical-induced damage. Cell Tissue Res 2005; 319(3): 439-45.
76. Sniekers YH, van Osch GJ, Jahr H, et al. Estrogen modulates iodoacetate-induced gene expression in bovine cartilage explants. J Orthop Res 2010; 28(5): 607-15.
77. Scranton PE Jr, McMaster JH, Diamond PE. Hormone suppression of DNA synthesis in cultured chondrocyte and osteosarcoma cell line. Clin Orthop Relat Res 1975; (112): 340-8.
78. Mackintosh D, Mason RM. Pharmacological actions of 17 betaoestradiol on articular cartilage chondrocytes and chondrosarcoma chondrocytes in the absence of oestrogen receptors. Biochim Biophys Acta 1988; 964(3): 295-302.
79. Talwar RM, Wong BS, Svoboda K, Harper RP. Effects of estrogen on chondrocyte proliferation and collagen synthesis in skeletally mature articular cartilage. J Oral Maxillofac Surg 2006; 64(4): 600-9.
80. Dayani N, Corvol MT, Robel P, et al. Estrogen receptors in cultured rabbit articular chondrocytes: influence of age. J Steroid Biochem 1988; 31(3): 351-6.
81. Blanchard O, Tsagris L, Rappaport R, et al. Age-dependent responsiveness of rabbit and human cartilage cells to sex steroids in vitro. J Steroid Biochem Mol Biol 1991; 40(4-6): 711-6.
82. Sniekers Y. Estrogen effects on cartilage and bone changes in models for osteoarthritis. PhD thesis. Available at: http://repub.eur.nl/res/pub/16814/090924_Sniekers,%20Yvonne%2 0Hendrika.pdf [Last accessed October 15 2013]
83. Sondergaard BC, Oestergaard S, Christiansen C, et al. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 2007; 56(8): 2674-8.
84. Luo Q, Li SS, He C, et al. Pulse electromagnetic fields effects on serum E2 levels, chondrocyte apoptosis, and matrix metalloproteinase-13 expression in ovariectomized rats. Rheumatol Int 2009; 29(8): 927-35.
85. Bay-Jensen AC, Tabassi NC, Sondergaard LV, et al. The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther 2009; 11(1): R9.
86. Hart DA, Achari Y. Alterations to cell metabolism in connective tissues of the knee after ovariohysterectomy in a rabbit model: are there implications for the postmenopausal athlete? Br J Sports Med 2010; 44(12): 867-71.
87. Ham KD, Carlson CS. Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J Bone Miner Res 2004; 19(5): 823-9.
88. Olson EJ, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on the prevalence and area of periarticular tibial osteophytes in surgically postmenopausal cynomolgus monkeys. Bone 2007; 41(2): 282-9.
89. Quasnichka HL, Anderson-MacKenzie JM, Bailey AJ. Subchondral bone and ligament changes precede cartilage degradation in guinea pig osteoarthritis. Biorheology 2006; 43(3-4): 389-97.
90. Calvo E, Castañeda S, Largo R, et al. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage 2007; 15(1): 69-77.
91. Castañeda S, Largo R, Calvo E, et al. Effects of estrogen deficiency and low bone mineral density on healthy knee cartilage in rabbits. J Orthop Res 2010; 28(6): 812-8.
92. Yang JH, Kim JH, Lim DS, Oh KJ. Effect of combined sex hormone replacement on bone/cartilage turnover in a murine model of osteoarthritis. Clin Orthop Surg 2012; 4(3): 234-41.
93. de Klerk BM, Schiphof D, Groeneveld FP, et al. Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review. Rheumatology (Oxford) 2009; 48(2): 104-12.
94. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum 2006; 54(10): 3194-204.
95. Nevitt MC, Felson DT, Williams EN, Grady D. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001; 44(4): 811-8.
96. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013; 8(2): 135-55.
97. Rosner IA, Malemud CJ, Goldberg VM, et al. Pathologic and metabolic responses of experimental osteoarthritis to estradiol and an estradiol antagonist. Clin Orthop Relat Res 1982; (171): 280-6.
98. Rosner IA, Boja BA, Goldberg VM, Moskowitz RW. Tamoxifen therapy in experimental osteoarthritis. Curr Ther Res 1983; 34(3): 409-14.
99. Colombo C, Butler M, Hickman L, et al. A new model of osteoarthritis in rabbits. II. Evaluation of anti-osteoarthritic effects of selected antirheumatic drugs administered systemically. Arthritis Rheum 1983; 26(9): 1132-9.
100. Tsai CL, Liu TK. Inhibition of estradiol-induced early osteoarthritic changes by tamoxifen. Life Sci 1992; 50(25): 1943-51.
101. Christgau S, Tankó LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004; 11(5): 508-18.
102. Høegh-Andersen P, Tankó LB, Andersen TL, et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther 2004; 6(2): R169-80.
103. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10(10): 1478-87.
104. Kwan Tat S, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010; 24(1): 51-70.
105. Wieland HA, Michaelis M, Kirschbaum BJ, Rudolphi KA. Osteoarthritis-an untreatable disease? Nat Rev Drug Discov 2005; 4(4): 331-44.
106. Funck-Brentano T, Lin H, Hay E, et al. Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One 2012; 7(3): e33543.
107. Strassle BW, Mark L, Leventhal L, et al. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis Cartilage 2010; 18(10): 1319-28.
108. Jones MD, Tran CW, Li G, et al. In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. Arthritis Rheum 2010; 62(9): 2726-35.
109. Panahifar A, Maksymowych WP, Doschak MR. Potential mechanism of alendronate inhibition of osteophyte formation in the rat model of post-traumatic osteoarthritis: evaluation of elemental strontium as a molecular tracer of bone formation. Osteoarthritis Cartilage 2012; 20(7): 694-702.
110. Muehleman C, Green J, Williams JM, et al. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002; 10(3): 226-33.
111. Shirai T, Kobayashi M, Nishitani K, et al. Chondroprotective effect of alendronate in a rabbit model of osteoarthritis. J Orthop Res 2011; 29(10): 1572-7.
112. Zhang L, Hu H, Tian F, et al. Enhancement of subchondral bone quality by alendronate administration for the reduction of cartilage degeneration in the early phase of experimental osteoarthritis. Clin Exp Med 2011; 11(4): 235-43.
113. Myers SL, Brandt KD, Burr DB, et al. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol 1999; 26(12): 2645-53.
114. Pelletier JP, Troncy E, Bertaim T, et al. Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging. J Rheumatol 2011; 38(1): 118-28.
115. Meyer JM, Farmer RW, Prenger MC. Risedronate but not alendronate slows disease progression in the guinea pig model of primary osteoarthritis. J Bone Miner Res 2001; 44: 5305 (Abstract SA472).
116. Meyer JM, Dansereau SM, Farmer RW, et al. Bisphosphonates structurally similar to risedronate (actonel) slow disease progression in the guinea pig model of primary osteoarthritis. Arthritis Rheum 2001; 44: 5307 (Abstract 1527).
117. Ding M, Danielsen CC, Hvid I. The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int 2008; 82(1): 77-86.
118. Thomsen J, Straarup T, Danielsen C, Oxlund H, Brüel A. No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis. Scand J Rheumatol 2013 Mar 26. [Epub ahead of print]
119. Carbone LD, Nevitt MC, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004; 50(11): 3516-25.
120. Spector TD, Conaghan PG, Buckland-Wright JC, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005; 7(3): R625-33.
121. Bingham CO 3rd, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006; 54(11): 3494-507.
122. Buckland-Wright JC, Messent EA, Bingham CO 3rd, et al. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 2007; 46(2): 257-64.
123. Neogi T, Nevitt MC, Ensrud KE, et al. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 2008; 67(10): 1427-30.
124. Garnero P, Aronstein WS, Cohen SB, et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008; 16(6): 660-6.
125. Laslett LL, Doré DA, Quinn SJ, et al. Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial. Ann Rheum Dis 2012; 71(8): 1322-8.
126. Laslett LL, Kingsbury SR, Hensor EM, et al. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann Rheum Dis 2014; 73(5): 824-30.
127. Granholm S, Lundberg P, Lerner UH. Expression of the calcitonin receptor, calcitonin receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation. J Cell Biochem 2008; 104(3): 920-33.
128. Pelletier JP, Boileau C, Altman RD, Martel-Pelletier J. Experimental models of osteoarthritis: usefulness in the development of disease-modifying osteoarthritis drugs/agents. Therapy 2010; 7(6): 621-34.
129. Manicourt DH, Altman RD, Williams JM, et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 1999; 42(6): 1159-67.
130. El Hajjaji H, Williams JM, Devogelaer JP, et al. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 2004; 12(11): 904-11.
131. Behets C, Williams JM, Chappard D, et al. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J Bone Miner Res 2004; 19(11): 1821-6.
132. Papaioannou NA, Triantafillopoulos IK, Khaldi L, et al. Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study. Osteoarthritis Cartilage 2007; 15(4): 386-95.
133. Nielsen RH, Bay-Jensen AC, Byrjalsen I, Karsdal MA. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage 2011; 19(4): 466-73.
134. Sondergaard BC, Catala-Lehnen P, Huebner AK, et al. Mice overexpressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthritis Cartilage 2012; 20(2): 136-43.
135. Kyrkos MJ, Papavasiliou KA, Kenanidis E, et al. Calcitonin delays the progress of early-stage mechanically induced osteoarthritis. In vivo, prospective study. Osteoarthritis Cartilage 2013; 21(7): 973-80.
136. Sondergaard BC, Madsen SH, Segovia-Silvestre T, et al. Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes. BMC Musculoskelet Disord 2010; 11: 62.
137. Chen-An P, Andreassen KV, Henriksen K, et al. The inhibitory effect of salmon calcitonin on tri-iodothyronine induction of early hypertrophy in articular cartilage. PLoS One 2012; 7(6): e40081.
138. Manicourt DH, Azria M, Mindeholm L, et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006; 54(10): 3205-11.
139. Karsdal MA, Byrjalsen I, Henriksen K, et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010; 18(2): 150-9.
140. Karsdal MA, Byrjalsen I, Bay-Jensen AC, et al. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 2010; 11: 125.
141. Karsdal MA, Alexandersen P, John MR, et al. Oral calcitonin demonstrated symptom-modifying efficacy and increased cartilage volume: results from a 2-year phase 3 trial in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2011; 19(Suppl 1): S35.
142. Armagan O, Serin DK, Calisir C, et al. Inhalation therapy of calcitonin relieves osteoarthritis of the knee. J Korean Med Sci 2012; 27(11): 1405-10.
143. Esenyel M, İçaǧasi{dotless}oǧlu A, Esenyel CZ. Effects of calcitonin on knee osteoarthritis and quality of life. Rheumatol Int 2013; 33(2): 423-7.
144. European Medicines Agency. European Medicines Agency recommends limiting long-term use of calcitonin medicines. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_ev ents/news/2012/07/news_detail_001573.jsp&mid=WC0b01ac0580 04d5c1 [Last accessed October 24 2013]
145. Chang JK, Chang LH, Hung SH, et al. Parathyroid hormone 1-34 inhibits terminal differentiation of human articular chondrocytes and osteoarthritis progression in rats. Arthritis Rheum 2009; 60(10): 3049-60.
146. Sampson ER, Hilton MJ, Tian Y, et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med 2011; 3(101): 101ra93.
147. Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage 2011; 19(10): 1228-36.
148. Eswaramoorthy R, Chang CC, Wu SC, et al. Sustained release of PTH(1-34) from PLGA microspheres suppresses osteoarthritis progression in rats. Acta Biomater 2012; 8(6): 2254-62.
149. Lugo L, Villalvilla A, Gómez R, et al. Effects of PTH [1-34] on synoviopathy in an experimental model of osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage 2012; 20(12): 1619-30.
150. Lafeber FP, van Laar JM. Strontium ranelate: ready for clinical use as disease-modifying osteoarthritis drug? Ann Rheum Dis 2013; 72(2): 157-61.
151. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001; 16(2): 299-308.
152. Tat SK, Pelletier JP, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone 2011; 49(3): 559-67.
153. Pelletier JP, Kapoor M, Fahmi H, et al. Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1β in the synovium. Ann Rheum Dis 2013; 72(2): 250-7.
154. Yu DG, Ding HF, Mao YQ, et al. Strontium ranelate reduces cartilage degeneration and subchondral bone remodeling in rat osteoarthritis model. Acta Pharmacol Sin 2013; 34(3): 393-402.
155. Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008; 67(3): 335-9.
156. Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTXII in postmenopausal women. Bone 2007; 40(1): 218-22.
157. Alexandersen P, Karsdal MA, Byrjalsen I, Christiansen C. Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis. Climacteric 2011; 14(2): 236-43.
158. Reginster JY, Badurski J, Bellamy N, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013; 72(2): 179-86.
159. Kwan Tat S, Amiable N, Pelletier JP, et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford) 2009; 48(12): 1482-90.
160. Pilichou A, Papassotiriou I, Michalakakou K, et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem 2008; 41(9): 746-9.
161. Shimizu S, Asou Y, Itoh S, et al. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/ osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007; 56(10): 3358-65.
162. Kadri A, Ea HK, Bazille C, et al. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008; 58(8): 2379-86.
163. Bellido M, Lugo L, Roman-Blas JA, et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Res Ther 2010; 12(4): R152.
164. Sagar DR, Ashraf S, Xu L, et al. Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. Ann Rheum Dis 2013 Jun 7. [Epub ahead of print]
165. Costa AG, Cusano NE, Silva BC, et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011; 7(8): 447-56.
166. Salminen-Mankonen HJ, Morko J, Vuorio E. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 2007; 8(2): 315-23.
167. Konttinen YT, Mandelin J, Li TF, et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum 2002; 46(4): 953-60.
168. Pelletier JP, Boileau C, Brunet J, et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004; 34(3): 527-38.
169. Vinardell T, Dejica V, Poole AR, et al. Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis. Osteoarthritis Cartilage 2009; 17(3): 375-83.
170. Connor JR, LePage C, Swift BA, et al. Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis. Osteoarthritis Cartilage 2009; 17(9): 1236-43.
171. McDougall JJ, Schuelert N, Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthritis Cartilage 2010; 18(10): 1355-7.
172. Hayami T, Zhuo Y, Wesolowski GA, et al. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012; 50(6): 1250-9.
173. Manicourt D, Beaulieu A, Garnero P, et al. Effect of treatment with the cathepsin-k inhibitor, balicatib, on cartilage volume and biochemical markers of bone and cartilage degradation in patients with painful knee osteoarthritis. Osteoarthritis Cartilage 2007; 15: C 130.
174. Tetlow LC, Woolley DE. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage 2001; 9(5): 423-31.
175. McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996; 125(5): 353-9.
176. Lane NE, Gore LR, Cummings SR, et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum 1999; 42(5): 854-60.
177. Felson DT, Niu J, Clancy M, et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum 2007; 56(1): 129-36.
178. Hunter DJ, Hart D, Snieder H, et al. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford) 2003; 42(11): 1311-6.
179. Muraki S, Dennison E, Jameson K, et al. Association of vitamin D status with knee pain and radiographic knee osteoarthritis. Osteoarthritis Cartilage 2011; 19(11): 1301-6.
180. Cao Y, Winzenberg T, Nguo K, et al. Association between serum levels of 25-hydroxyvitamin D and osteoarthritis: a systematic review. Rheumatology (Oxford) 2013; 52(7): 1323-34.
181. McAlindon T, LaValley M, Schneider E, et al. Effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis: a randomized controlled trial. JAMA 2013; 309(2): 155-62.
182. Hardy MM, Seibert K, Manning PT, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 2002; 46(7): 1789-803.
183. Gosset M, Berenbaum F, Levy A, et al. Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a mechanosensitive gene. Arthritis Res Ther 2006; 8(4): R135.
184. Candelario-Jalil E, Slawik H, Ridelis I, et al. Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum. J Mol Neurosci 2005; 27(3): 303-10.
185. Moreno-Rubio J, Herrero-Beaumont G, Tardio L, et al. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin and RANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis Rheum 2010; 62(2): 478-88.
186. Li X, Ellman M, Muddasani P, et al. Prostaglandin E2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the pathophysiology of osteoarthritis. Arthritis Rheum 2009; 60(2): 513-23.
187. Zeng L, An S, Goetzl EJ. EP4/EP2 receptor-specific prostaglandin E2 regulation of interleukin-6 generation by human HSB.2 early T cells. J Pharmacol Exp Ther 1998; 286(3): 1420-6.
188. Mitsui H, Aoyama T, Furu M, et al. Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability. Arthritis Res Ther 2011; 13(5): R146.
189. Li N, Rivéra-Bermúdez MA, Zhang M, et al. LXR modulation blocks prostaglandin E2 production and matrix degradation in cartilage and alleviates pain in a rat osteoarthritis model. Proc Natl Acad Sci USA 2010; 107(8): 3734-9.
190. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4(2): 111-21.
191. Himanen JP, Saha N, Nikolov DB. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 2007; 19(5): 534-42.
192. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006; 4(2): 111-21.
193. Matsuo K, Otaki N. Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr 2012; 6(2): 148-56.
194. Kwan Tat S, Pelletier JP, Amiable N, et al. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. Arthritis Rheum 2008; 58(12): 3820-30.
195. Kwan Tat S, Pelletier JP, Amiable N, et al. Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. Arthritis Res Ther 2009; 11(4): R119.
196. Valverde-Franco G, Pelletier JP, Fahmi H, et al. In vivo bonespecific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis. Arthritis Rheum 2012; 64(11): 3614-25.
197. Riazi AM, Kwon SY, Stanford WL. Stem cell sources for regenerative medicine. Methods Mol Biol 2009; 482: 55-90.
198. Diekman BO, Guilak F. Stem cell-based therapies for osteoarthritis: challenges and opportunities. Curr Opin Rheumatol 2013; 25(1): 119-26.
199. Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther 2008; 10(5): 223.
200. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol 2013; 9(10): 584-94.
201. Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 2002; 10(3): 199-206.
202. Varma HS, Dadarya B, Vidyarthi A. The new avenues in the management of osteo-arthritis of knee--stem cells. J Indian Med Assoc 2010; 108(9): 583-5.
203. Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med 2010; 38(6): 1110-6.
204. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee 2012; 19(6): 902-7.
205. Lee KB, Wang VT, Chan YH, Hui JH. A novel, minimallyinvasive technique of cartilage repair in the human knee using arthroscopic microfracture and injections of mesenchymal stem cells and hyaluronic acid-a prospective comparative study on safety and short-term efficacy. Ann Acad Med Singapore 2012; 41(11): 511-7.
206. Wakitani S, Okabe T, Horibe S, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011; 5(2): 146-50.
207. Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy 2013; 29(4): 748-55.
208. Autologous mesenchymal stem cells for treating knee osteoarthritis. Manag Care 2013; 22(8): 15-6.
209. Nie H, Lee CH, Tan J, et al. Musculoskeletal tissue engineering by endogenous stem/progenitor cells. Cell Tissue Res 2012; 347(3): 665-76.
210. Gerter R, Kruegel J, Miosge N. New insights into cartilage repair-the role of migratory progenitor cells in osteoarthritis. Matrix Biol 2012; 31(3): 206-13.
211. Lee CH, Cook JL, Mendelson A, et al. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet 2010; 376(9739): 440-8.
212. Mendelson A, Frank E, Allred C, et al. Chondrogenesis by chemotactic homing of synovium, bone marrow, and adipose stem cells in vitro. FASEB J 2011; 25(10): 3496-504.
213. Re'em T, Witte F, Willbold E, et al. Simultaneous regeneration of articular cartilage and subchondral bone induced by spatially presented TGF-beta and BMP-4 in a bilayer affinity binding system. Acta Biomater 2012; 8(9): 3283-93.
214. Unterman SA, Gibson M, Lee JH, et al. Hyaluronic acid-binding scaffold for articular cartilage repair. Tissue Eng Part A 2012; 18(23-24): 2497-506.
215. Coburn JM, Gibson M, Monagle S, et al. Bioinspired nanofibers support chondrogenesis for articular cartilage repair. Proc Natl Acad Sci USA 2012; 109(25): 10012-7.
216. Johnson K, Zhu S, Tremblay MS, et al. A stem cell-based approach to cartilage repair. Science 2012;336(6082):717-21
217. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.
218. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-20.
219. Kim MJ, Son MJ, Son MY, et al. Generation of human induced pluripotent stem cells from osteoarthritis patient-derived synovial cells. Arthritis Rheum 2011; 63(10): 3010-21.
220. Wei Y, Zeng W, Wan R, et al. Chondrogenic differentiation of induced pluripotent stem cells from osteoarthritic chondrocytes in alginate matrix. Eur Cell Mater 2012; 23:1-12.
221. Diekman BO, Christoforou N, Willard VP, et al. Cartilage tissue engineering using differentiated and purified induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109(47): 19172-7.
222. Hiramatsu K, Sasagawa S, Outani H, et al. Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors. J Clin Invest 2011; 121(2): 640-57.
223. Outani H, Okada M, Hiramatsu K, et al. Induction of chondrogenic cells from dermal fibroblast culture by defined factors does not involve a pluripotent state. Biochem Biophys Res Commun 2011; 411(3): 607-12.
224. Genetics Home Reference. What is gene therapy? Available at: http://ghr.nlm.nih.gov/handbook/therapy/genetherapy [Last accessed 15th August 2013]
225. Rai MF, Lang A, Sieber M, Schmidt MFG. Conditioning and Scaffolding of Chondrocytes: Smart Steps Towards Osteoarthritis Gene Therapy. In: Kang C, editors. Gene Therapy Applications. Germany: InTech, 2011: 137-64.
226. Bandara G, Robbins PD, Georgescu HI, et al. Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992; 11(3): 227-31.
227. Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy and its tortuous path into the clinic. Transl Res 2013; 161(4): 205-16.
228. Evans CH, Ghivizzani SC, Kang R, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999; 42(1): 1-16.
229. Ghivizzani SC, Gouze E, Gouze JN, et al. Perspectives on the use of gene therapy for chronic joint diseases. Curr Gene Ther 2008; 8(4): 273-86.
230. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy of the rheumatic diseases: 1998 to 2008. Arthritis Res Ther 2009; 11(1): 209.
231. Evans CH, Ghivizzani SC, Robbins PD. Getting arthritis gene therapy into the clinic. Nat Rev Rheumatol 2011; 7(4): 244-9.
232. Bandara G, Mueller GM, Galea-Lauri J, et al. Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci USA 1993; 90(22): 10764-8.
233. Pelletier JP, Caron JP, Evans C, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40(6): 1012-9.
234. Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999; 154(4): 1159-69.
235. Frisbie DD, Ghivizzani SC, Robbins PD, et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9(1): 12-20.
236. Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J Orthop Res 2004; 22(4): 742-50.
237. Guo WS, Ma L, Li ZR. Suppression of articular cartilage breakdown in osteoarthritis by interleukin-1 receptor antagonist using ex vivo gene therapy. Zhonghua Yi Xue Za Zhi 2004; 84(10): 853-6.
238. Wang HJ, Yu CL, Kishi H, et al. Suppression of experimental osteoarthritis by adenovirus-mediated double gene transfer. Chin Med J (Engl) 2006; 119(16): 1365-73.
239. Zhang X, Yu C, Xushi, et al. Direct chitosan-mediated gene delivery to the rabbit knee joints in vitro and in vivo. Biochem Biophys Res Commun 2006; 341(1): 202-8.
240. Chen B, Qin J, Wang H, et al. Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits. Exp Mol Med 2010; 42(10): 684-95.
241. Watson RS, Broome TA, Levings PP, et al. scAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther 2013; 20(6): 670-7.
242. Goodrich LR, Phillips JN, McIlwraith CW, et al. Optimization of scAAVIL-1ra In vitro and In vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis. Mol Ther Nucleic Acids 2013; 2:e70.
243. Mi Z, Ghivizzani SC, Lechman ER, et al. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum 2000; 43(11): 2563-70.
244. Chen LX, Lin L, Wang HJ, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 2008; 16(2): 174-84.
245. Hsieh JL, Shen PC, Shiau AL, et al. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther 2009; 20(2): 147-58.
246. Hsieh JL, Shen PC, Shiau AL, et al. Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis. J Orthop Res 2010; 28(10): 1300-6.
247. Orth P, Kaul G, Cucchiarini M, et al. Transplanted articular chondrocytes co-overexpressing IGF-I and FGF-2 stimulate cartilage repair in vivo. Knee Surg Sports Traumatol Arthrosc 2011; 19(12): 2119-30.
248. Ha CW, Noh MJ, Choi KB, Lee KH. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 in degenerative arthritis patients. Cytotherapy 2012; 14(2): 247-56.
249. Cho JJ, Kim TW, Park YM, Jeong EG, Noh MJ, Lee KH, Lee BS. A placebo controlled phase IIb clinical study of Tissue Gene-C (TG-C) in patients with osteoarthritis. 16th Annual Meeting of American Society of Gene & Cell Therapy, Salt Lake City, Utah, May 15-18, 2013, Abstract 565
250. van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthritis Cartilage 2007; 15(3): 237-44.
251. Ansboro S, Greiser U, Barry F, Murphy M. Strategies for improved targeting of therapeutic cells: implications for tissue repair. Eur Cell Mater 2012; 23: 310-8;discussion 318-9.
252. Kraus VB, Burnett B, Coindreau J, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011; 19(5): 515-42.
253. Berenbaum F. The quest for the Holy Grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther 2007; 9(6): 111.